Type 2 diabetes patients assessment of the COMODITY12 mHealth system
Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial....
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Alliance for Innovation (EAI)
2015-11-01
|
Series: | EAI Endorsed Transactions on Pervasive Health and Technology |
Subjects: | |
Online Access: | http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283 |
id |
doaj-36ec2f6c08364be691209deea09fee5a |
---|---|
record_format |
Article |
spelling |
doaj-36ec2f6c08364be691209deea09fee5a2020-11-25T01:44:33ZengEuropean Alliance for Innovation (EAI)EAI Endorsed Transactions on Pervasive Health and Technology2411-71452015-11-01141510.4108/icst.pervasivehealth.2015.259283Type 2 diabetes patients assessment of the COMODITY12 mHealth systemPrzemyslaw Kardas0Krzysztof Lewandowski1First Department of Family Medicine, Medical University of Lodz; przemyslaw.kardas@umed.lodz.plDepartment of Endocrinology & Metabolic Diseases, Medical University of LodzBackground: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283mhealthcomodity12diabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Przemyslaw Kardas Krzysztof Lewandowski |
spellingShingle |
Przemyslaw Kardas Krzysztof Lewandowski Type 2 diabetes patients assessment of the COMODITY12 mHealth system EAI Endorsed Transactions on Pervasive Health and Technology mhealth comodity12 diabetes |
author_facet |
Przemyslaw Kardas Krzysztof Lewandowski |
author_sort |
Przemyslaw Kardas |
title |
Type 2 diabetes patients assessment of the COMODITY12 mHealth system |
title_short |
Type 2 diabetes patients assessment of the COMODITY12 mHealth system |
title_full |
Type 2 diabetes patients assessment of the COMODITY12 mHealth system |
title_fullStr |
Type 2 diabetes patients assessment of the COMODITY12 mHealth system |
title_full_unstemmed |
Type 2 diabetes patients assessment of the COMODITY12 mHealth system |
title_sort |
type 2 diabetes patients assessment of the comodity12 mhealth system |
publisher |
European Alliance for Innovation (EAI) |
series |
EAI Endorsed Transactions on Pervasive Health and Technology |
issn |
2411-7145 |
publishDate |
2015-11-01 |
description |
Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed. |
topic |
mhealth comodity12 diabetes |
url |
http://eudl.eu/doi/10.4108/icst.pervasivehealth.2015.259283 |
work_keys_str_mv |
AT przemyslawkardas type2diabetespatientsassessmentofthecomodity12mhealthsystem AT krzysztoflewandowski type2diabetespatientsassessmentofthecomodity12mhealthsystem |
_version_ |
1725027946620518400 |